# Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials

Source: https://onco.cc/key-papers/paper-sakamoto-cancer-immunol-immunother/  
OnCo record `paper-sakamoto-cancer-immunol-immunother` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one technology page, indexed on Europe PMC as PubMed record 16133112 and published in Cancer immunology, immunotherapy; the citing page links this DOI, which is how the record was matched.

## Summary

The benefits of immunochemotherapy employing the biological response modifier polysaccharide K (PSK) for patients with curatively resected colorectal cancer was reassessed by means of a meta-analysis of data with center randomization from 1,094 patients enrolled in three clinical trials. In all three trials, patients were followed up for at least 5 years after surgery and enrollment of the last patient and outcomes for standard chemotherapy were compared with those for chemotherapy plus PSK. The endpoints were overall survival and disease-free survival; and intent-to-treat analysis was performed without patient exclusion. Data were analyzed using the weighted average of the individual log hazard ratios. The overall survival risk ratio for all eligible patients was 0.71 (95% confidence interval (CI): 0.55-0.90; P=0.006), and the disease-free survival risk ratio was 0.72 (95% CI: 0.58-0.90; P=0.003). The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK can improve both survival and disease-free survival of patients with curatively resected colorectal cancer.

Indexed on Europe PMC as PubMed record 16133112 (DOI 10.1007/s00262-005-0054-1). Matched by DOI alone: one technology page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Cancer immunology, immunotherapy
- Year: 2006
- DOI: 10.1007/s00262-005-0054-1
- Authors: Sakamoto J, Morita S, Oba K, et al.
- What it means: One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Cancer Immunol Immunother 2006: https://doi.org/10.1007/s00262-005-0054-1
- PubMed: https://pubmed.ncbi.nlm.nih.gov/16133112/
- Europe PMC: https://europepmc.org/article/MED/16133112

## Connected records

- technologies: [PSK (Krestin) mushroom polysaccharide as adjuvant therapy](https://onco.cc/technologies/psk-krestin-adjuvant/)
- journals: [Cancer immunology, immunotherapy](https://onco.cc/journals/cancer-immunology-immunotherapy/)

---
JSON: https://onco.cc/api/v1/entities/paper-sakamoto-cancer-immunol-immunother.json